AACOMmunities

Federal Funding Opportunities and Resources

Below is a selected list of timely federal funding opportunities that are relevant to the osteopathic medical education community. AACOM updates this resource frequently.  Please bookmark the page for your reference. For a comprehensive listing of federal funding opportunities, please visit Grants.gov.   

Featured Opportunities

March 16 - March 27

National Institutes of Health

Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)

Application Due: May 16, 2020

The purpose of this funding is to promote development of innovative, enabling tools and technologies in the areas of kidney, urologic, and hematologic diseases.

Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional)

Letter of Intent Due: 30 days prior to application due date

Application Due: July 31, 2020

The National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.

Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R21 Clinical Trial Optional)

Letter of Intent Due: 30 days prior to application due date

Application Due: July 31, 2020

The National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors.

Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)

Application Due: May 7, 2020

This funding seeks innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials.

Innovations in HIV Prevention, Testing, Adherence and Retention to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)

Application Due: May 7, 2020

This funding seeks innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials.

NIDA Small Research Grant Program (R03 Clinical Trial Required)

Application Due: June 16, 2020

The NIDA Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology.

Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)

Application Due: October 5, 2020

The funding encourages research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)

Application Due: October 13, 2020

The funding encourages research investigating the roles of extracellular RNA (exRNA) carrier subclasses in biological processes relevant to substance use disorders (SUDs) and/or HIV infection, latency, or pathogenesis in the CNS. Applicants may propose to investigate biological mechanisms involving exRNA carrier subclasses or propose to develop improved technologies to investigate extracellular vesicles or other exRNA carriers.

NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)

Application Due: June 16, 2020

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.


March 2 - March 13

Centers for Disease Control and Prevention

Building Capacity for National Public Health Institutes

Application Due Date: May 4, 2020

The funding seeks to build upon activities supported by CDC through partnerships with Ministries of Health, National Public Health Institutes (NPHI), and organizations that have capacity by providing technical assistance supporting the establishment and development of strong NPHIs globally.

Enhancing Disease Detection in Newborns: Building Capacity in Public Health Laboratories

Application Due Date: May 14, 2020

This funding will increase the capacity and capability of state and territorial newborn screening laboratories to test for newborn screening conditions as recommended by the U.S. Department of Health and Human Services (HHS) Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). Early detection of these conditions, whose symptoms are not clinically observable at birth, save thousands of infants and children from disability and death through early detection and treatment.

Sickle Cell Data (SCD) Collection Program

Application Due Date: May 11, 2020

There is no national surveillance of SCD. Consequently, there are large gaps in our current understanding of the natural course of the disease and its variable manifestations from one patient to the next. There is also a lack of consistent scientific data to facilitate informed decision-making that may lead to significant health improvements in the SCD community. Funding will allow for a population-based surveillance system for the identification of individuals with SCD and the standardized collection of information about their clinical history.

National Institutes of Health

Alzheimers Disease Research Centers (P30 Clinical Trial Not Allowed)

Letter of Intent Due: August 15, 2020

Application Due Date: September 15, 2020

This funding opportunity invites applications for P30 Alzheimer's Disease Research Centers (ADRCs). NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. 

Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)

Application Due Date: April 7, 2020

The National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This funding is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

Harnessing Natural Killer (NK) Cells to Prevent, Control, or Eradicate HIV (R01 Clinical Trial Not Allowed)

Letter of Intent Due: 30 days prior to application deadline

Application Due Date: July 28, 2020 (earliest submission is June 29, 2020)

This Funding Opportunity Announcement (FOA) will support basic, translational, and clinical research to improve the understanding of the effector or immunoregulatory potentials of NK cells for HIV prevention, control and/or eradication.

Gastrointestinal (GI) and Microbiome Explorers: Development of Swallowable Smart Pills or Devices for Precision Nutrition, Microbiome and Digestive Disease Applications (R21/R33 Clinical Trial Required)

Letter of Intent Due: May 18, 2020

Application Due Date: June 18, 2020

The funding will support development of tools/devices for sampling or monitoring of diet- gastro-intestinal (GI)(contents and mucosa) and microbial interactions (GI- Microbiome Explorer). It is anticipated that successful completion of the projects completed under this FOA will yield implementable devices/tools for gastroenterological research or other clinical applications.